Daiichi Sankyo

Activities: Packaging Research & Development Pharmaceutical

Trending Articles

  1. Limula bags US patent for cell & gene therapy manufacturing technology The automated technology is designed to streamline the cell and gene therapy production process, paving the way for point-of-care manufacturing within hospital facilities
  2. Roquette debuts Health & Pharma Solutions, Nutrition & Bioindustry subsidiaries The company has created two new organisations; Roquette Health & Pharma and Roquette Nutrition & Bioindustry, following its acquisition of IFF Pharma Solutions
  3. ProBioGen to provide cell line development services to Polpharma Biologics The biotech will help produce a high-quality, high-yield biosimilar using CHO.RiGHT, its cell line development platform
  4. DFE Pharma achieves ISO 22301 certification for BCMS DFE Pharma's Business Continuity Management System (BCMS) at its head office in Goch, Germany helps it to effectively maintain its operations
  5. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows...

Upcoming event

Boosting Sustainability and Efficiency in Pharma Manufacturing

14 May 2025 | Virtual See all

Related Content

Research & Development

Daiichi Sankyo and BioMed X Institute join forces to develop multi-specific biologics for cancer therapy

Through this collaboration, they aim to discover and develop novel target combinations for bi- and multi-specific biologics for the treatment of solid tumours
Regulatory

AstraZeneca & Daiichi Sankyo's Enhertu bags another approval for gastric cancer applications

The HER2-targeting ADC has received conditional approval owing to the results of the DESTINY-Gastric06 Phase II trial

Therapeutic: datopotamab deruxtecan for breast cancer

Of all the various forms of breast cancer, triple negative is the most aggressive subtype
Research & Development

AstraZeneca and Daiichi Sankyo reveal phase 3 lung cancer study

Results for the TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy
Drug Delivery

ProLynx collaborates with Daiichi Sankyo on drug delivery

The collaboration will evaluate the utility of the releasable linker technology in half-life extension of small-molecule drugs after intravitreal injection
Finance

Heptares Therapeutics enters agreement with Daichi Sankyo

The collaboration aims to discover and develop novel, small-molecules for the treatment of pain
Pharmaceutical

Amgen and Daiichi Sankyo to commercialise biosimilars in Japan

The exclusive agreement includes nine biosimilars in late-stage development
Subscribe now